Letter abstract
Nature Medicine 14, 676 - 680 (2008)
Published online: 11 May 2008 | doi:10.1038/nm1769
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination
Roberto Chiarle1,2, Cinzia Martinengo1,5, Cristina Mastini1,3,5, Chiara Ambrogio1,2, Valentina D'Escamard4, Guido Forni3 & Giorgio Inghirami1,2,4
An ideal vaccination strategy against tumors relies on specific antigens that are required for tumor maintenance1. For lymphoma, vaccination with subject-specific immunoglobulin idiotypes has had the most promising results2, 3. Here we show that DNA vaccination with plasmids encoding portions of the cytoplasmic domain of anaplastic lymphoma kinase (ALK), which has been translocated in different fusion proteins necessary for the growth of anaplastic large cell lymphoma (ALCL)4, protects mice from local and systemic lymphoma growth. The protection is potent and long lasting and elicits ALK-specific interferon-
responses and CD8+ T cell–mediated cytotoxicity. A combination of chemotherapy and vaccination significantly enhanced the survival of mice challenged with ALK+ lymphomas. These findings indicate that ALK represents an ideal tumor antigen for vaccination-based therapies of ALCL and possibly other ALK+ human tumors4, 5, 6, 7.
- Center for Experimental Research and Medical Studies, University of Torino, Via Santena 7, 10126 Torino, Italy.
- Department of Biomedical Sciences and Human Oncology, University of Torino, Via Santena 7, 10126 Torino, Italy.
- Molecular Biotechnology Center, Department of Clinical and Biological Sciences, University of Torino, Via Nizza 52, 10126 Torino, Italy.
- Department of Pathology and New York Cancer Center, New York University School of Medicine, 550 First Avenue, New York 10016, USA.
- These authors contributed equally to this work.
Correspondence to: Roberto Chiarle1,2 e-mail: roberto.chiarle@unito.it
Correspondence to: Giorgio Inghirami1,2,4 e-mail: giorgio.inghirami@unito.it
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Can we apply the T H 1-T H 2 paradigm to all lymphocytes?Nature Immunology News and Views (01 Oct 2001)
Can we apply the T H 1-T H 2 paradigm to all lymphocytes?Nature Immunology News and Views (01 Oct 2001)
See all 3 matches for News And ViewsRESEARCH
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic targetNature Medicine Article (01 Jun 2005)
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastomaNature Letters to Editor (16 Oct 2008)
See all 34 matches for Research
